<p>根据 Garland Capital Management Inc.最近向证券交易委员会提交的 13F 表格，该公司在第三季度将其在 AbbVie Inc.（纽约证券交易所代码：ABBV - 免费报告）的持股减少了 76.7%。该公司在季度内出售了 7,123 股后，持有 2,160 股 AbbVie 的股票。AbbVie 约占 Garland Capital Management Inc.投资组合的 6.9%，是其第三大持股。截至最近的 SEC 文件，Garland Capital Management Inc.在 AbbVie 的持股价值为 500,000 美元。</p>
<ul>
<li>AbbVie 的前景：二月份的下跌看起来像是买入信号</li>
</ul>
<p>其他一些对冲基金和机构投资者也增加或减少了在该公司的股份。Ellenbecker Investment Group 在第三季度将其在 AbbVie 的持股增加了 0.8%。Ellenbecker Investment Group 现在持有 5,334 股 AbbVie 的股票，价值 1,235,000 美元，在此期间又购买了 44 股。Security National Bank of Sioux City Iowa IA 在第三季度将其在 AbbVie 的股份增加了 0.3%。Security National Bank of Sioux City Iowa IA 现在持有 15,382 股 AbbVie 的股票，价值 3,562,000 美元，在此期间又购买了 45 股。Matthew Goff Investment Advisor LLC 在第三季度将其在 AbbVie 的持股增加了 0.3%。Matthew Goff Investment Advisor LLC 现在持有 17,561 股 AbbVie 的股票，价值 4,066,000 美元，在上个季度又购买了 45 股。Centennial Wealth Advisory LLC 在第三季度将其在 AbbVie 的股份增加了 2.2%。Centennial Wealth Advisory LLC 现在持有 2,089 股 AbbVie 的股票，价值 484,000 美元，在此期间又购买了 45 股。最后，Willner &amp; Heller LLC 在第三季度将其在 AbbVie 的持股增加了 0.6%。Willner &amp; Heller LLC 现在持有 7,596 股 AbbVie 的股票，价值 1,759,000 美元，在上个季度又购买了 46 股。70.23% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>AbbVie 的关键新闻</h2>
<p>以下是本周影响 AbbVie 的关键新闻：</p>
<ul>
<li>积极情绪：摩根士丹利将其目标价上调至 270 美元，并维持 “增持” 评级，表明机构分析师对 AbbVie 当前水平有双位数的上涨空间的信心。阅读更多。</li>
<li>积极情绪：公司对 2026 年全年的利润预测高于预期，得益于新型免疫药物（Skyrizi, Rinvoq）的强劲销售，支持了持续的收入和盈利增长的案例。阅读更多。</li>
<li>积极情绪：市场评论和一些分析师将财报后的回调视为买入机会，指出机构的积累、稳定的现金流和强劲的股息是中期回报的支撑。阅读更多。</li>
<li>积极情绪：来自日本的新现实世界 Rinvoq 数据增强了该药物在强直性脊柱炎中的可及市场，并强化了 AbbVie 免疫学业务的增长前景。阅读更多。</li>
<li>中性情绪：管理层围绕 “新增长引擎” 构建了财报电话会议——Skyrizi/Rinvoq 和其他新产品在推动增长方面发挥主导作用，这支持了长期故事，但并未消除短期波动。阅读更多。</li>
<li>中性情绪：第四季度的业绩在收入上超出预期，并显示出强劲的利润/收益杠杆，确认了产品的势头，尽管某些领域面临阻力。阅读更多。</li>
<li>消极情绪：在财报发布后，股价最初下跌，投资者关注第一季度每股收益和收入展望低于预期，尽管该季度的业绩超出预期——这是对指导失误的经典短期反应。阅读更多。</li>
<li>消极情绪：AbbVie 将 2026 年第一季度每股收益指导设定在 2.97–3.01 美元（相比于约 3.11 美元的共识），并给出了低于市场的收入指导，造成了对 2026 年增长节奏的短期不确定性。阅读更多。</li>
<li>消极情绪：更广泛的报道突显了投资者的 “焦虑” 和分化反应——对中期基本面持乐观态度，但对短期比较和估值感到担忧——保持了波动性。阅读更多。</li>
</ul>
<h2>AbbVie 股票上涨 2.0%</h2>
<ul>
<li>3 只 “永恒股票” 在市场不稳定时持有</li>
</ul>
<p>ABBV 股票在周五开盘价为 223.50 美元。该公司的 50 日简单移动平均线为 223.74 美元，200 日简单移动平均线为 219.41 美元。AbbVie Inc.的 52 周低点为 164.39 美元，52 周高点为 244.81 美元。该股票的市值为 3950.1 亿美元，市盈率为 94.70，PEG 比率为 0.89，贝塔值为 0.35。</p>
<p>AbbVie（纽约证券交易所代码：ABBV - 获取免费报告）最近于 2 月 4 日（星期三）发布了季度财报。该公司报告本季度每股收益为 2.71 美元，超出分析师一致预期的 2.65 美元，超出 0.06 美元。该公司在本季度的收入为 166.2 亿美元，而分析师预期为 163.9 亿美元。AbbVie 的股本回报率为-4,184.47%，净利润率为 6.91%。该公司的季度收入与去年同期相比增长了 10.0%。去年同期，该公司每股收益为 2.16 美元。AbbVie 已将其 2026 财年的指导设定为每股收益 14.370-14.570 美元，并将 2026 年第一季度的指导设定为每股收益 2.970-3.010 美元。分析师平均预计 AbbVie Inc.在当前财年将发布每股收益 12.31 美元。</p>
<h2>华尔街分析师的看法</h2>
<ul>
<li>AbbVie 认购期权激增 2,599%：追踪大额押注</li>
</ul>
<p>几位股票分析师对该股票发表了看法。Sanford C. Bernstein 在周四的报告中重申了对艾伯维的 “市场表现” 评级。华尔街 Zen 在 1 月 3 日的报告中将艾伯维的评级从 “强力买入” 下调至 “买入”。Guggenheim 在 10 月 20 日的研究报告中将艾伯维的目标价从 227.00 美元提高至 242.00 美元，并给予该股票 “买入” 评级。Evercore 在周三的研究报告中将艾伯维的目标价从 232.00 美元下调至 228.00 美元，并对该股票设定了 “跑赢大盘” 评级。最后，摩根士丹利在周四的研究报告中将艾伯维的目标价从 269.00 美元上调至 270.00 美元，并给予该股票 “超配” 评级。两位投资分析师给予该股票 “强力买入” 评级，十一位分析师给予 “买入” 评级，九位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，平均目标价为 251.00 美元。</p>
<p><strong>阅读我们对艾伯维的最新股票分析</strong></p>
<h2>关于艾伯维</h2>
<p>（免费报告）</p>
<p>艾伯维是一家全球性的、以研究为驱动的生物制药公司，于 2013 年从雅培实验室分拆而成，总部位于伊利诺伊州北芝加哥。该公司专注于发现、开发和商业化针对复杂且常常是慢性医疗条件的治疗方案。其业务涵盖研究与开发、制造、监管事务和商业化，重点是将专业药物推向多个治疗领域的市场。</p>
<p>艾伯维的产品组合和研发管道涵盖多个主要治疗类别，包括免疫学、肿瘤学、神经科学、病毒学和女性健康。</p>
<h2>相关文章</h2>
<ul>
<li>五只我们更看好的股票超过艾伯维</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>黄金市场崩溃的那一天</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>你的银行账户不再安全</li>
<li>他刚刚又准确预测了黄金……</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在艾伯维吗？</h2>
<p>在考虑艾伯维之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而艾伯维并不在名单上。</p>
<p>虽然艾伯维目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

2 倍做多纳斯达克生物技术 ETF - ProShares

医疗业 ETF - Vanguard

医药突破 ETF - ALPS

<p>Garland Capital Management Inc. 在第三季度将其在艾伯维（AbbVie Inc.）的持股减少了 76.7%，目前持有 2,160 股，价值 50 万美元。其他机构投资者也对艾伯维的持仓进行了调整。尽管对艾伯维最近的财报和指引存在混合情绪，分析师们仍对其增长潜力持乐观态度，特别是由于新型免疫药物的强劲销售。艾伯维的股票目前交易价格为 223.50 美元，市值为 3950.1 亿美元，市盈率为 94.70</p>

<p>Garland Capital Management Inc. trimmed its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 76.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,160 shares of the company's stock after selling 7,123 shares during the quarter. AbbVie makes up about 6.9% of Garland Capital Management Inc.'s investment portfolio, making the stock its 3rd largest holding. Garland Capital Management Inc.'s holdings in AbbVie were worth $500,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根据 Garland Capital Management Inc.最近向证券交易委员会提交的 13F 表格，该公司在第三季度将其在 AbbVie Inc.（纽约证券交易所代码：ABBV - 免费报告）的持股减少了 76.7%。该公司在季度内出售了 7,123 股后，持有 2,160 股 AbbVie 的股票。AbbVie 约占 Garland Capital Management Inc.投资组合的 6.9%，是其第三大持股。截至最近的 SEC 文件，Garland Capital Management Inc.在 AbbVie 的持股价值为 500,000 美元。</p>
</div><ul>
<li>AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal</li>
</ul>
<div class="lb-trans"><ul>
<li>AbbVie 的前景：二月份的下跌看起来像是买入信号</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Ellenbecker Investment Group raised its holdings in AbbVie by 0.8% in the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company's stock worth $1,235,000 after purchasing an additional 44 shares during the period. Security National Bank of Sioux City Iowa IA raised its stake in shares of AbbVie by 0.3% in the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company's stock worth $3,562,000 after buying an additional 45 shares during the period. Matthew Goff Investment Advisor LLC lifted its position in shares of AbbVie by 0.3% during the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company's stock valued at $4,066,000 after buying an additional 45 shares in the last quarter. Centennial Wealth Advisory LLC grew its stake in shares of AbbVie by 2.2% during the 3rd quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company's stock valued at $484,000 after acquiring an additional 45 shares during the period. Finally, Willner &amp; Heller LLC increased its holdings in AbbVie by 0.6% in the 3rd quarter. Willner &amp; Heller LLC now owns 7,596 shares of the company's stock worth $1,759,000 after acquiring an additional 46 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者也增加或减少了在该公司的股份。Ellenbecker Investment Group 在第三季度将其在 AbbVie 的持股增加了 0.8%。Ellenbecker Investment Group 现在持有 5,334 股 AbbVie 的股票，价值 1,235,000 美元，在此期间又购买了 44 股。Security National Bank of Sioux City Iowa IA 在第三季度将其在 AbbVie 的股份增加了 0.3%。Security National Bank of Sioux City Iowa IA 现在持有 15,382 股 AbbVie 的股票，价值 3,562,000 美元，在此期间又购买了 45 股。Matthew Goff Investment Advisor LLC 在第三季度将其在 AbbVie 的持股增加了 0.3%。Matthew Goff Investment Advisor LLC 现在持有 17,561 股 AbbVie 的股票，价值 4,066,000 美元，在上个季度又购买了 45 股。Centennial Wealth Advisory LLC 在第三季度将其在 AbbVie 的股份增加了 2.2%。Centennial Wealth Advisory LLC 现在持有 2,089 股 AbbVie 的股票，价值 484,000 美元，在此期间又购买了 45 股。最后，Willner &amp; Heller LLC 在第三季度将其在 AbbVie 的持股增加了 0.6%。Willner &amp; Heller LLC 现在持有 7,596 股 AbbVie 的股票，价值 1,759,000 美元，在上个季度又购买了 46 股。70.23% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Key AbbVie News</h2>
<div class="lb-trans"><h2>AbbVie 的关键新闻</h2>
</div><p>Here are the key news stories impacting AbbVie this week:</p>
<div class="lb-trans"><p>以下是本周影响 AbbVie 的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Morgan Stanley raised its price target to $270 and kept an &#34;overweight&#34; call, signaling institutional analyst conviction that AbbVie has double‑digit upside from current levels. Read More.</li>
<li>Positive Sentiment: Company forecasts for full‑year 2026 profit came in above estimates, driven by strong sales of newer immunology drugs (Skyrizi, Rinvoq), supporting the case for continued top‑line and earnings growth. Read More.</li>
<li>Positive Sentiment: Market commentary and some analysts view the post‑earnings pullback as a buying opportunity, pointing to institutional accumulation, durable cash flow, and a strong dividend as anchors for medium‑term returns. Read More.</li>
<li>Positive Sentiment: New real‑world Rinvoq data from Japan bolsters the drug's addressable market for ankylosing spondylitis and reinforces growth prospects for AbbVie’s immunology franchise. Read More.</li>
<li>Neutral Sentiment: Management framed the earnings call around &#34;new growth engines&#34; — Skyrizi/Rinvoq and other launches taking the lead in driving growth, which supports the long‑term story but doesn't eliminate near‑term volatility. Read More.</li>
<li>Neutral Sentiment: Q4 results beat on revenue and showed strong margin/earnings leverage, confirming product momentum even as some segments face headwinds. Read More.</li>
<li>Negative Sentiment: Shares initially gapped down after the print as investors focused on a softer-than‑expected Q1 EPS and revenue outlook despite the quarter’s beats — a classic near‑term reaction to guidance misses. Read More.</li>
<li>Negative Sentiment: AbbVie set Q1 2026 EPS guidance at $2.97–$3.01 (vs. ~3.11 consensus) and gave revenue guidance below the street, creating short‑term uncertainty about the cadence of 2026 growth. Read More.</li>
<li>Negative Sentiment: Broader coverage highlighted investor &#34;angst&#34; and a bifurcated reaction — bullish on medium‑term fundamentals but worried about near‑term comps and valuation — keeping volatility elevated. Read More.</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：摩根士丹利将其目标价上调至 270 美元，并维持 “增持” 评级，表明机构分析师对 AbbVie 当前水平有双位数的上涨空间的信心。阅读更多。</li>
<li>积极情绪：公司对 2026 年全年的利润预测高于预期，得益于新型免疫药物（Skyrizi, Rinvoq）的强劲销售，支持了持续的收入和盈利增长的案例。阅读更多。</li>
<li>积极情绪：市场评论和一些分析师将财报后的回调视为买入机会，指出机构的积累、稳定的现金流和强劲的股息是中期回报的支撑。阅读更多。</li>
<li>积极情绪：来自日本的新现实世界 Rinvoq 数据增强了该药物在强直性脊柱炎中的可及市场，并强化了 AbbVie 免疫学业务的增长前景。阅读更多。</li>
<li>中性情绪：管理层围绕 “新增长引擎” 构建了财报电话会议——Skyrizi/Rinvoq 和其他新产品在推动增长方面发挥主导作用，这支持了长期故事，但并未消除短期波动。阅读更多。</li>
<li>中性情绪：第四季度的业绩在收入上超出预期，并显示出强劲的利润/收益杠杆，确认了产品的势头，尽管某些领域面临阻力。阅读更多。</li>
<li>消极情绪：在财报发布后，股价最初下跌，投资者关注第一季度每股收益和收入展望低于预期，尽管该季度的业绩超出预期——这是对指导失误的经典短期反应。阅读更多。</li>
<li>消极情绪：AbbVie 将 2026 年第一季度每股收益指导设定在 2.97–3.01 美元（相比于约 3.11 美元的共识），并给出了低于市场的收入指导，造成了对 2026 年增长节奏的短期不确定性。阅读更多。</li>
<li>消极情绪：更广泛的报道突显了投资者的 “焦虑” 和分化反应——对中期基本面持乐观态度，但对短期比较和估值感到担忧——保持了波动性。阅读更多。</li>
</ul>
</div><h2>AbbVie Stock Up 2.0%</h2>
<div class="lb-trans"><h2>AbbVie 股票上涨 2.0%</h2>
</div><ul>
<li>3 “Forever Stocks” to Hold When the Market Won’t Sit Still</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只 “永恒股票” 在市场不稳定时持有</li>
</ul>
</div><p>Shares of ABBV stock opened at $223.50 on Friday. The company's fifty day simple moving average is $223.74 and its two-hundred day simple moving average is $219.41. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The stock has a market cap of $395.01 billion, a P/E ratio of 94.70, a PEG ratio of 0.89 and a beta of 0.35.</p>
<div class="lb-trans"><p>ABBV 股票在周五开盘价为 223.50 美元。该公司的 50 日简单移动平均线为 223.74 美元，200 日简单移动平均线为 219.41 美元。AbbVie Inc.的 52 周低点为 164.39 美元，52 周高点为 244.81 美元。该股票的市值为 3950.1 亿美元，市盈率为 94.70，PEG 比率为 0.89，贝塔值为 0.35。</p>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts' consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The business's quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter last year, the business posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>AbbVie（纽约证券交易所代码：ABBV - 获取免费报告）最近于 2 月 4 日（星期三）发布了季度财报。该公司报告本季度每股收益为 2.71 美元，超出分析师一致预期的 2.65 美元，超出 0.06 美元。该公司在本季度的收入为 166.2 亿美元，而分析师预期为 163.9 亿美元。AbbVie 的股本回报率为-4,184.47%，净利润率为 6.91%。该公司的季度收入与去年同期相比增长了 10.0%。去年同期，该公司每股收益为 2.16 美元。AbbVie 已将其 2026 财年的指导设定为每股收益 14.370-14.570 美元，并将 2026 年第一季度的指导设定为每股收益 2.970-3.010 美元。分析师平均预计 AbbVie Inc.在当前财年将发布每股收益 12.31 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><ul>
<li>AbbVie Call Options Spike 2,599%: Tracking the Big Bet</li>
</ul>
<div class="lb-trans"><ul>
<li>AbbVie 认购期权激增 2,599%：追踪大额押注</li>
</ul>
</div><p>Several equities analysts have weighed in on the stock. Sanford C. Bernstein reaffirmed a &#34;market perform&#34; rating on shares of AbbVie in a report on Thursday. Wall Street Zen downgraded shares of AbbVie from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Saturday, January 3rd. Guggenheim increased their price target on AbbVie from $227.00 to $242.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, October 20th. Evercore lowered their price objective on AbbVie from $232.00 to $228.00 and set an &#34;outperform&#34; rating on the stock in a research report on Wednesday. Finally, Morgan Stanley upped their price objective on AbbVie from $269.00 to $270.00 and gave the stock an &#34;overweight&#34; rating in a research note on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and an average price target of $251.00.</p>
<div class="lb-trans"><p>几位股票分析师对该股票发表了看法。Sanford C. Bernstein 在周四的报告中重申了对艾伯维的 “市场表现” 评级。华尔街 Zen 在 1 月 3 日的报告中将艾伯维的评级从 “强力买入” 下调至 “买入”。Guggenheim 在 10 月 20 日的研究报告中将艾伯维的目标价从 227.00 美元提高至 242.00 美元，并给予该股票 “买入” 评级。Evercore 在周三的研究报告中将艾伯维的目标价从 232.00 美元下调至 228.00 美元，并对该股票设定了 “跑赢大盘” 评级。最后，摩根士丹利在周四的研究报告中将艾伯维的目标价从 269.00 美元上调至 270.00 美元，并给予该股票 “超配” 评级。两位投资分析师给予该股票 “强力买入” 评级，十一位分析师给予 “买入” 评级，九位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，平均目标价为 251.00 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on AbbVie</strong></p>
<div class="lb-trans"><p><strong>阅读我们对艾伯维的最新股票分析</strong></p>
</div><h2>About AbbVie</h2>
<div class="lb-trans"><h2>关于艾伯维</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.</p>
<div class="lb-trans"><p>艾伯维是一家全球性的、以研究为驱动的生物制药公司，于 2013 年从雅培实验室分拆而成，总部位于伊利诺伊州北芝加哥。该公司专注于发现、开发和商业化针对复杂且常常是慢性医疗条件的治疗方案。其业务涵盖研究与开发、制造、监管事务和商业化，重点是将专业药物推向多个治疗领域的市场。</p>
</div><p>AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.</p>
<div class="lb-trans"><p>艾伯维的产品组合和研发管道涵盖多个主要治疗类别，包括免疫学、肿瘤学、神经科学、病毒学和女性健康。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相关文章</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>The day the gold market broke</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>He just nailed another gold prediction …</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过艾伯维</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>黄金市场崩溃的那一天</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>你的银行账户不再安全</li>
<li>他刚刚又准确预测了黄金……</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在艾伯维吗？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑艾伯维之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而艾伯维并不在名单上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然艾伯维目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Garland Capital Management Inc. Lowers Stake in AbbVie Inc. $ABBV

Market Beat

艾伯维

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

动态生物技术与基因组 ETF - Invesco

生物科技 ETF - VanEck Vectors

医疗业 ETF - SPDR

基因改革 ETF - ARK

美国制药 ETF - iShares

纽交所高增长板生物技术指数 ETF - First Trust

Invesco Nasdaq Biotechnology ETF

Garland Capital Management Inc. 减持了艾伯维公司 $ABBV 的股份